### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

### SCHEDULE 13D/A

## Under the Securities Exchange Act of 1934 (Amendment No. 12)\*

MARKER THERAPEUTICS, Inc.

(Name of Issuer)

# COMMON STOCK, \$0.001 PAR VALUE PER SHARE

(Title of Class of Securities)

57055L107

(CUSIP Number)

# William Sullivan, 10 Market Street, #773 Camana Bay Grand Cayman, KY1-9006 CAYMAN ISLANDS, 345-640-3300 (Name, Address and Telephone Number of Person

Authorized to Receive Notices and Communications)

November 09, 2020

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of \$240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

# CUSIP No. 57055L107

13D/A

# 1. NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

### EASTERN CAPITAL LIMITED

2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
	(see instructions)
	(a) 🗆
	(b) □

3. SEC USE ONLY

4. SOURCE OF FUNDS (see instructions)

### WC

5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

# 6. CITIZENSHIP OR PLACE OF ORGANIZATION

## **CAYMAN ISLANDS**

7. SOLE VOTING POWER

NUMBER OF	-0-
SHARES	8. SHARED VOTING POWER
BENEFICIALLY OWNED BY	4,466,668*
EACH	9. SOLE DISPOSITIVE POWER
REPORTING PERSON WITH	-0-
FERSON WITH	10. SHARED DISPOSITIVE POWER
	4,466,668*

### 11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

### 4,466,668\*

12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)

# 13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

9.2%

14. TYPE OF REPORTING PERSON (see instructions)

### со

\* As of the filing date and as described in Items 4, 5(a) and 5(b), Eastern Capital Limited beneficially owns 4,050,001 shares of Common Stock and 416,667 shares of Common Stock issuable upon exercise of the Series F-1 Warrant.

# CUSIP No. 57055L107

13D/A

# 1. NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

# PORTFOLIO SERVICES LTD.

- CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP 2. (see instructions)
  - (a) 🗆
  - (b)
- 3. SEC USE ONLY

SOURCE OF FUNDS (see instructions) 4.

## 00

5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) 

#### CITIZENSHIP OR PLACE OF ORGANIZATION 6.

## **CAYMAN ISLANDS**

7. SOLE VOTING POWER

NUMBER OF	-0- 8. SHARED VOTING POWER
SHARES BENEFICIALLY	4.466.668*
OWNED BY EACH	9. SOLE DISPOSITIVE POWER
REPORTING PERSON WITH	-0- 10. SHARED DISPOSITIVE POWER
	4,466,668*

## 11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

### 4,466,668\*

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES 12. (see instructions)  $\Box$ 

#### 13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

9.2%

14. TYPE OF REPORTING PERSON (see instructions)

### со

\* As of the filing date and as described in Items 4, 5(a) and 5(b), Portfolio Services Ltd. beneficially owns 4,050,001 shares of Common Stock and 416,667 shares of Common Stock issuable upon exercise of the Series F-1 Warrant.

CUSIP No. 5705	L107 13D/A	Page 4 of 6
1. NAMES OF	REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)	
KENNETH	3. DART	
	E APPROPRIATE BOX IF A MEMBER OF A GROUP	
(see instruc (a) □	ions)	
(a) □ (b) □		
3. SÉC USE C	NLY	
4. SOURCE C	F FUNDS (see instructions)	
00		
5. CHECK BO	X IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)	
6. CITIZENSH	IP OR PLACE OF ORGANIZATION	
CAYMAN IS	iLANDS	
	7. SOLE VOTING POWER	
NUMBER OF	-0-	
SHARES	8. SHARED VOTING POWER	
BENEFICIALLY OWNED BY	4,466,668*	
EACH	9. SOLE DISPOSITIVE POWER	
REPORTING		
PERSON WITH		
	10. SHARED DISPOSITIVE POWER	

4,466,668\*

# 11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

### 4,466,668\*

12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions) □

# 13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

# 9.2%

14. TYPE OF REPORTING PERSON (see instructions)

# IN

\*As of the filing date and as described in Items 4, 5(a) and 5(b), Kenneth B. Dart beneficially owns 4,050,001 shares of Common Stock and 416,667 shares of Common Stock issuable upon exercise of the Series F-1 Warrant.

# CUSIP No. 57055L107

13D/A

This Amendment No. 12 to Schedule 13D (this "Amendment No. 12") relates to shares of common stock, par value \$0.001 per share (the "Common Stock"), of Marker Therapeutics, Inc., (the "Issuer"). This Amendment No. 12 amends the original Schedule 13D filed with the U.S. Securities and Exchange Commission by the Reporting Persons as previously amended by Amendments No. 1 through 11 (the "Schedule 13D"). Except as otherwise specified in this Amendment No. 12, all previous Items are unchanged. Defined terms used herein but not otherwise defined have the meanings set forth in the Schedule 13D.

### Item 4. Purpose of Transaction.

The Reporting Persons acquired the Issuer's securities for investment purposes.

The Series D-1 Warrant to purchase 416,667 shares of Common Stock of the Issuer at the exercise price of \$9.00 per share with an expiration date of September 9, 2020, was not exercised by the Reporting Persons before such expiration.

The Reporting Persons currently have no plans or proposals which relate to or would result in any transaction, event, or action enumerated in paragraphs (a) through (j) of Item 4 of Schedule 13D.

# Item 5. Interest in Securities of the Issuer.

Item 5(a)–(b)

Eastern Capital Limited beneficially owns 4,466,668 shares of the Issuer's Common Stock, representing 9.2% of the Issuer's outstanding Common Stock. Eastern Capital Limited has shared voting and dispositive power of the shares it beneficially owns with its parent, Portfolio Services Ltd. and Kenneth B. Dart.

Portfolio Services Ltd., as the owner of all of the outstanding shares of Eastern Capital Limited, indirectly beneficially owns 4,466,668 shares of the Issuer's Common Stock, representing 9.2% of the Issuer's outstanding Common Stock. Portfolio Services Ltd. has shared voting and dispositive power of the shares it beneficially owns.

As a result of Kenneth B. Dart's ownership of all of the outstanding shares of Portfolio Services Ltd., he indirectly beneficially owns 4,466,668 shares of the Issuer's Common Stock, representing 9.2% of the Issuer's outstanding Common Stock. Kenneth B. Dart has shared voting and dispositive power of the shares he beneficially owns.

The percentage ownership noted in this Schedule 13D/A is based on 48,025,102 shares outstanding as of October 31, 2020 as reported in the Issuer's Form 10Q filed with the U.S. Securities Exchange Commission on November 9, 2020, plus 416,667 shares of Common Stock that may be issued upon exercise of the Series F-1 Warrant held by the Reporting Persons.

## Item 7. Material to Be Filed as Exhibits.

Exhibit 1 – Joint Filing Agreement

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
EASTERN CAPITAL LIMITED
11/13/2020
Date
/s/ Kenneth B. Dart
Signature
Kenneth B. Dart, Director
Name/Title
PORTFOLIO SERVICES LTD.
11/13/2020
Date
/s/ Kenneth B. Dart
Signature
Kenneth B. Dart, Director
Name/Title
KENNETH B. DART
11/13/2020
Date
/s/ Kenneth B. Dart
Signature
Kenneth B. Dart
Name/Title

13D/A SIGNATURE

Page 6 of 6

CUSIP No. 57055L107

# EXHIBIT 1

# JOINT FILING AGREEMENT

The undersigned agree to the joint filing of Schedule 13D (including any and all amendments thereto) with respect to the shares of common stock of Marker Therapeutics, Inc. The undersigned further agree and acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning it contained therein, but shall not be responsible for the completeness and accuracy of the other, except to the extent that it knows or has reason to believe that such information is inaccurate.

EASTERN CAPITAL LIMITED 11/13/2020
Date
/s/ Kenneth B. Dart
Signature
Kenneth B. Dart, Director
Name/Title
PORTFOLIO SERVICES LTD.
11/13/2020
Date
/s/ Kenneth B. Dart
Signature
Kenneth B. Dart, Director
Name/Title
Name/Title
KENNETH B. DART
11/13/2020
Date
/////www.sthe D. Davit
/s/ Kenneth B. Dart
Signature
Kenneth B. Dart
Name/Title